Cord blood LC-PUFA composition and allergic diseases during the first 10 yr. Results from the LISAplus study

Marie Standl1, Hans Demmelmaier2, Berthold Koletzko2 & Joachim Heinrich1

1Institute of Epidemiology I, Helmholtz Zentrum München – German Research Centre for Environmental Health, Neuherberg, Germany; 2University of Munich Medical Centre, Dr. von Hauner Children’s Hospital, Munich, Germany

To cite this article: Standl M, Demmelmaier H, Koletzko B, Heinrich J. Cord blood LC-PUFA composition and allergic diseases during the first 10 yr. Results from the LISAplus study. Pediatr Allergy Immunol 2014: 25: 344–350.

Abstract

Background: It has been suggested that n-6 and n-3 long-chain polyunsaturated fatty acids (LC-PUFAs) in blood are associated with risk of allergic diseases, although results are inconclusive. Low levels of n-6 LC-PUFA and high levels of n-3 LC-PUFA are anticipated to have beneficial effects. Pregnancy is considered a critical time period for imprinting the developing immune system. We examined whether n-6 LC-PUFA, n-3 LC-PUFA concentrations or the n-6/n-3 ratio in cord blood (CB) serum are associated with allergic diseases up to the age of 10 yr.

Methods: This analysis included 436 children from the Munich LISAplus birth cohort study. Information on doctor-diagnosed asthma, hay fever/allergic rhinitis, and eczema was collected using questionnaires completed at the ages 6 and 10 yr, and for eczema additionally at 2 yr. Specific immunoglobulin E (IgE) against inhalant allergens was measured at 6 and 10 yr. Fatty acid composition was measured by gas chromatography in serum from CB and from blood collected at 2, 6, and 10 yr. Associations between n-3, n-6 LC-PUFA concentrations, and the n-6/n-3 ratio in CB serum and allergic diseases or atopy were assessed using generalized estimating equations (GEE) considering the longitudinal structure. Models were adjusted for LC-PUFA concentrations at follow-up and potential confounding factors.

Results: There was no significant association between n-3 LC-PUFA, n-6 LC-PUFA, or the n-6/n-3 ratio in CB serum with eczema, asthma, hay fever/allergic rhinitis, or aeroallergen sensitization.

Conclusions: There is no indication of a beneficial effect of increased n-3 LC-PUFA in CB serum on the development of any of the disease entities.
Cord blood (CB) LC-PUFA composition reflects the LC-PUFA supply of the offspring around birth (8).

Therefore, we hypothesize that higher n-3 LC-PUFA, lower n-6 LC-PUFA concentrations, and a lower n-6/n-3 ratio in CB serum are associated with lower prevalence of doctor-diagnosed asthma, eczema, hay fever/allergic rhinitis, as well as aeroallergen sensitization up to 10 yr of age, even after accounting for later LC-PUFA status.

Based on these questions for each year of age up to 10 yr, combined variables were defined. For eczema, three variables were defined for having physician-diagnosed eczema between birth and 2 yr, 3–6 yr and 7–10 yr of age. For asthma and hay fever/allergic rhinitis, only the last two variables were defined, due to the low prevalence between birth and 2 yr. Controls were defined by a negative answer, or if no answer was given, as long as the questionnaire was returned.

Blood tests

The analysis of fatty acids was performed by transesterification of glycerophospholipid fatty acids into methyl esters and their gas chromatographic separation and quantification (10). This procedure has been previously described in detail for the analysis of serum from CB and from blood samples collected at the ages of 2 and 6 yr (11, 12), and was also applied for blood samples collected at the age of 10 yr. Total n-6 LC-PUFA and n-3 LC-PUFA was calculated by summing up all measured n-6 fatty acids and n-3 fatty acids, respectively, with 20 carbon atoms or more. The n-6/n-3 ratio was calculated by dividing total n-6 LC-PUFA by total n-3 LC-PUFA.

Specific serum IgE concentrations were assayed by the CAP-RAST FEIA system (Pharmacia Diagnostics, Freiburg, Germany) according to the manufacturer’s instructions. Screening tests were used to test allergic sensitization against inhalant allergens (sx1: Dermatophagoides pteronyssinus, cat, dog, rye, timothy grass, Cladosporium herbarum, birch, and mugwort). Children were assigned as IgE positive, if their IgE values exceeded 0.35 kU/l for at least one of the measured inhalant allergens, otherwise as controls.

Statistical analysis

N-3, n-6 LC-PUFAs, or n-6/n-3 ratio measured at birth, 2, 6 or 10 yr of age with values exceeding mean ± 4 SD were defined as outliers and treated like missing values in subsequent analysis (Fig. S1). Differences between LC-PUFA levels stratified by case-control status were tested using Student’s t-test for two independent samples.

Considering the longitudinal data structure, generalized estimating equations (GEE) were applied to model the effect of n-3, n-6 LC-PUFA concentrations, and the n-6/n-3 ratio in CB serum on eczema, asthma, hay fever/allergic rhinitis, as well as aeroallergen sensitization (13). An autoregressive working correlation structure was assumed (AR-1).

The GEE model returns one estimate for the variables, which were measured once (CB serum LC-PUFA composition) and one combined estimate for the variables, which were measured at the various follow-up time points (LC-PUFA composition at follow-up).

The GEE models were additional adjusted for the time-dependent variables time of follow-up (2, 6, and 10 yr for eczema; 6 and 10 yr for asthma, hay fever/allergic rhinitis, and aeroallergen sensitization), age, n-3, n-6 LC-PUFA, and n-6/n-3 ratio, respectively, at follow-up and the total sum of fatty acids as well as parental education, sex, maternal age at birth, and parental atopy. Additionally, the child’s BMI, birth...
weight, and exclusive breastfeeding for more than 4 months, as well as maternal factors such as smoking during pregnancy, BMI before pregnancy, atopy and parity were tested as potential confounders, but not included in the final models, because there was no significant effect. The GEE model does not require that each subject have the same number of data points. To rule out a potential bias that may be introduced by non-random loss to follow-up, additional sensitivity analyses were conducted. This analysis was restricted to children with complete information on eczema, asthma, hay fever/allergic rhinitis, or aeroallergen sensitization and fatty acid measurements at all time points.

Further, general linear models for each follow-up were conducted, regressing the n-3, n-6 LC-PUFA concentrations, and the n-6/n-3 ratio in CB serum on eczema, asthma, hay fever/allergic rhinitis, or aeroallergen sensitization. The models were adjusted for age, n-3, n-6 LC-PUFA, and n-6/n-3 ratio, respectively, at follow-up and the total sum of fatty acids as well as parental education, sex, maternal age at birth, and parental atopy.

The effect estimates are presented as odds ratio (OR) with corresponding 95% confidence interval (95%-CI). Significance was defined as a two-sided alpha level of 5%.

Statistical analyses were performed using R, version 2.15.2 (www.R-project.org) (14) and the function geeglm() from package ‘geepack’ to fit GEE models.

Results

Information on CB serum n-3, n-6 LC-PUFAs, or the n-6/n-3 ratio, at least one of the diseases entities and LC-PUFA composition in blood at one or more follow-ups at 2, 6, or 10 yr of age was available for 436 children. The participant flow is illustrated in Fig. S1.

Basic characteristics of the study population are presented in Table 1. Of the 436 children with CB serum fatty acid measurements, 280 children were examined at 2 yr, 277 children at 6 yr, and 243 children at 10 yr. The period prevalence of eczema was constantly high up to age 6 and decreased afterwards, whereas the prevalence of hay fever/allergic rhinitis, asthma, and aeroallergen sensitization increased after age 6 yr. The mean percentage of n-3 as well as n-6 LC-PUFA was higher in CB serum than in blood at later follow-ups, but the n-6/n-3 ratio remained stable.

All investigated variables were tested for differences between children who participated in this analysis with the remaining children from the Munich study center who were not included (Table S1). There was a lower percentage of girls, and a higher parental education level in study participants (p = 0.0394 and p = 0.0229, respectively).

Table 2 shows mean and SD of n-3 LC-PUFA, n-6 LC-PUFA concentrations, and n-6/n-3 ratio in CB serum in children with (cases) and without (controls) eczema, asthma, hay fever/allergic rhinitis, or aeroallergen sensitization, respectively. It was tested whether the mean of n-3 LC-PUFA, n-6 LC-PUFA concentrations, and n-6/n-3 ratio in CB serum differs significantly between cases and controls. Children with aeroallergen sensitization at 10 yr had lower n-6 LC-PUFA concentrations in CB serum (mean in controls: 25.6 vs. mean in cases: 25.2, p = 0.0326).

Table 3 shows mean and SD of n-3 LC-PUFA, n-6 LC-PUFA concentrations and n-6/n-3 ratio cross-sectional at each follow-up in children with (cases) and without (controls) eczema, asthma, hay fever/allergic rhinitis, or aeroallergen sensitization, respectively. Children with eczema at 2 yr have significant lower concentrations of n-3 LC-PUFA (4.6 vs. 4.4, p = 0.0337) and a significant higher n-6/n-3 ratio (2.9 vs. 3.1, p = 0.0074). Additionally, lower n-3 LC-PUFA concentrations were observed in children with asthma at 6 yr (4.5 vs. 4.1, p = 0.0032) and aeroallergen sensitization at age 6 yr (4.5 vs. 4.3, p = 0.0205).

The results of GEE on allergic diseases are presented in Table 4. There was no significant association between n-3 LC-PUFA, n-6 LC-PUFA concentrations, or the n-6/n-3 ratio in CB serum with any of the investigated outcomes. Thus, the CB serum LC-PUFA concentrations do not appear to have any effect on allergic disease risk at any time point investigated.

| Table 1: Basic characteristics of the study population. Values are presented as mean (SD) or percentage |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Birth                                                                                                           | 2 yr                                                                                                           | 6 yr                                                                                                           | 10 yr                                                                                                           |
| N                                                                | 436                                                                                                          | 280                                                                                                          | 277                                                                                                          | 243                                                                                                           |
| Eczema, %                                                         | 15                                                                                                           | 14                                                                                                          | 7                                                                |                                                                                                                |
| Asthma, %                                                         | 3                                                               | 5                                                              |                                                                                                               |                                                                                                                |
| Hay fever/allergic rhinitis, %                                    | 3                                                               | 13                                                             |                                                                                                               |                                                                                                                |
| Aeroallergen sensitization, %                                     | 24                                                             | 43                                                             |                                                                                                               |                                                                                                                |
| n-6 LC-PUFA *                                                     | 25.3 (1.5)                                                     | 13.3 (1.5)                                                    | 13.6 (1.6)                                                     | 15 (1.6)                                                      |
| n-3 LC-PUFA *                                                     | 8.1 (1.6)                                                     | 4.5 (0.8)                                                     | 4.5 (0.9)                                                     | 4.8 (1.1)                                                      |
| n-6/n-3 ratio                                                     | 3.3 (0.7)                                                     | 3.0 (0.5)                                                     | 3.1 (0.6)                                                     | 3.2 (0.6)                                                      |
| Total sum of fatty acids (mg/l)                                   | 644.7 (103.3)                                                  | 1146.5 (160.9)                                               | 1198.8 (182.4)                                               | 1257.4 (202.5)                                               |
| Parental education (% high)                                       | 82                                                             |                                                                                                               |                                                                                                               |                                                                                                                |
| Sex (% female)                                                    | 43                                                             |                                                                                                               |                                                                                                               |                                                                                                                |
| Age (yr)                                                          | 2.01 (0.03)                                                    | 6.1 (0.2)                                                    | 10.2 (0.2)                                                    |                                                                                                                |
| Maternal age (yr)                                                 | 32.7 (3.9)                                                    |                                                                                                               |                                                                                                               |                                                                                                                |
| Parental atopy (% yes)                                            | 64                                                             |                                                                                                               |                                                                                                               |                                                                                                                |

*n-6 and n-3 LC-PUFAs are presented as percentage of total fatty acids
Children with eczema at a given age was significantly associated with lower concentrations of n-3 LC-PUFA at this same age [OR = 0.71, 95%-CI = (0.55–0.92), p = 0.0085].

In an additional sensitivity analysis, the GEE models were restricted to children with complete information on eczema, asthma, hay fever/allergic rhinitis, or aeroallergen sensitization and fatty acid measurements at all time points (Table S2). This analysis showed similar results. Additionally, there was a borderline significant inverse association between n-6 LC-PUFA in CB serum and eczema [0.83 (0.68–1.02), p = 0.0784].

In a further sensitivity analysis, general linear models for each follow-up were conducted (Table S3). The results from the GEE models were confirmed by this analysis. There was also no significant association between CB serum n-3, n-6 LC-PUFA concentrations, or the n-6/n-3 ratio with any of the allergic diseases. Children with eczema at the age of 6 yr had significantly lower concentrations of n-3 LC-PUFA at the same age [0.60 (0.38–0.97), p = 0.0047], but not at 2 yr [0.70 (0.45–1.09), p = 0.1189] or 10 yr [0.90 (0.51–1.59), p = 0.7212]. Aeroallergen sensitization at age 6 yr was inverse associated with n-3 LC-PUFA at the same age [0.68 (0.47–0.98), p = 0.0407], but not at 10 yr [0.90 (0.69–1.18), p = 0.4619].

### Discussion

This study investigated the association between n-3 and n-6 LC-PUFA composition as well as the n-6/n-3 ratio in CB serum and the development of eczema, asthma, hay fever/allergic rhinitis and allergic sensitization up to 10 yr of age.
Eczema
Asthma
Hay fever or allergic rhinitis

348

the association between atopic diseases and diet (7, 16) serum fatty acid concentrations are an important risk factor for therefore, Newson et al. concluded that it is unlikely that CB significant any more after adjustment for multiple testing, and life. There was some evidence; however, the results were not atopic outcomes, but without adjustment for fatty acids later in published data on fatty acid concentrations in CB serum and were included using a longitudinal model. fatty acids measurements starting from birth to 10 yr of age

eczema exhibit lower levels of n-3 LC-PUFA.

the same time point were entered in the model, children with disease entities. When fatty acid concentrations measured at

PUFA concentrations in CB serum on any of the investigated cohort.

using longitudinal data from the Munich LISAplus birth
during the last 4 wk of pregnancy and allergic diseases in the birth cohort, the association between maternal dietary intake

24) or lactation (25, 26), although most of these studies had a short follow-up period of 1 year (20, 22, 24, 26), a small sample size with few cases (20, 23) or the results were not significant anymore after adjustment for multiple comparisons (24, 26). Olsen et al. (22) used registry data to follow-up children at 16 yr of age and found a strong reduction of asthma and especially atopic asthma risk in the intervention group.

Several intervention studies have been conducted to investigate the association between n-3 LC-PUFA status and atopic diseases aiming to increase the n-3 LC-PUFA concentrations during pregnancy (19–24) or lactation (25–27). The studies in which cytokines were measured, reported a more favorable immune response (19–21, 25, 27).

Nevertheless, it is not clear whether these immunological changes can avoid clinical manifestation of allergic diseases. The studies which investigated clinical outcomes, reported less or less severe atopic diseases in the intervention group (20, 22–24, 26), although most of these studies had a short follow-up period of 1 year (20, 23, 24, 26), a small sample size with few cases (20, 23) or the results were not significant anymore after adjustment for multiple comparisons (24, 26).

The findings from observational studies investigating food intake could not be confirmed by interventional studies. This might be due to the above mentioned limitations or due to residual confounding in observational studies, whereas dietary intake is related to a certain lifestyle. Donahue et al. (29) investigated the associations between n-3 and n-6 PUFAs in maternal diet, maternal blood, and CB plasma and found the strongest correlation for DHA+EPA. Therefore, the assessment of n-3 LC-PUFA in diet and blood should lead to similar

| Table 4 | Results of a GEE in which n-3, n-6 LC-PUFA concentrations, and n-6/n-3 ratio in CB serum are regressed on allergic diseases. ORs are adjusted for parental education, sex, time of follow-up (2 yr, 6 yr or 10 yr for eczema; 6 yr and 10 yr for asthma, hay fever/allergic rhinitis and aeroallergen sensitization), age, maternal age at birth, parental atopy, total sum of fatty acids, as well as LC-PUFA concentrations at follow-up (FU) were included |
|---------------------------------|---------------------------------|---------------------------------|
| **n-3 LC-PUFA**                | **n-6 LC-PUFA**                | **n-6/n-3 ratio**              |
| **N**                          | **OR**                         | **95%-CI**                     | **p-value** | **N**                          | **OR**                         | **95%-CI**                     | **p-value** | **N**                          | **OR**                         | **95%-CI**                     | **p-value** |
| Eczema                         |                                 |                                |                     | Asthma                        |                                 |                                |                     | Hay fever or allergic rhinitis |                                 |                                |                     |
| CB                             | 431                            | 1.01                           | (0.87–1.16)         | 0.9055                        | 432                            | 0.94                           | (0.80–1.11)         | 0.4936                        | 434                            | 0.96                           | (0.70–1.31)         | 0.7829 |
| FU                             | 0.71                           | (0.55–0.92)                    | 0.0086             | 1.00                          | (0.88–1.15)                    | 0.9580                        | 1.51                           | (0.98–2.33)                    | 0.0600                        |                                |                     |
| Asthma                         |                                 |                                |                     |                                |                                |                                |                     |                                 |                                |                                |                     |
| CB                             | 335                            | 1.00                           | (0.75–1.35)        | 0.9884                        | 334                            | 1.31                           | (0.93–1.84)        | 0.1266                        | 337                            | 1.17                           | (0.52–2.59)        | 0.6903 |
| FU                             | 1.03                           | (0.55–1.94)                    | 0.9713             | 0.77                          | (0.58–1.01)                    | 0.0579                        | 0.71                           | (0.35–1.48)                    | 0.3526                        |                                |                     |
| Hay fever or allergic rhinitis |                                 |                                |                     |                                |                                |                                |                     |                                 |                                |                                |                     |
| CB                             | 334                            | 0.98                           | (0.76–1.25)        | 0.8569                        | 333                            | 0.88                           | (0.67–1.11)        | 0.2548                        | 336                            | 0.88                           | (0.52–1.49)        | 0.6416 |
| FU                             | 0.82                           | (0.52–1.29)                    | 0.3915             | 0.96                          | (0.77–1.19)                    | 0.7014                        | 1.56                           | (0.85–2.83)                    | 0.1495                        |                                |                     |
| Aeroallergen sensitization     |                                 |                                |                     |                                |                                |                                |                     |                                 |                                |                                |                     |
| CB                             | 336                            | 1.01                           | (0.87–1.18)        | 0.8494                        | 335                            | 0.87                           | (0.74–1.01)        | 0.0742                        | 338                            | 0.88                           | (0.62–1.23)        | 0.4407 |
| FU                             | 0.82                           | (0.67–1.00)                    | 0.0514             | 1.07                          | (0.94–1.20)                    | 0.3140                        | 1.34                           | (0.96–1.86)                    | 0.0849                        |                                |                     |

*n-6 and n-3 LC-PUFAs are presented as percentage of total fatty acids

after accounting for LC-PUFA concentrations in blood using longitudinal data from the Munich LISAplus birth cohort.

We could not find a protective effect of elevated n-3 LC-PUFA concentrations in CB serum on any of the investigated disease entities. When fatty acid concentrations measured at the same time point were entered in the model, children with eczema exhibit lower levels of n-3 LC-PUFA.

To our knowledge, this is the first study in which repeated fatty acids measurements starting from birth to 10 yr of age were included using a longitudinal model.

The ALSPAC study is the only observational study which published data on fatty acid concentrations in CB serum and atopic outcomes, but without adjustment for fatty acids later in life. There was some evidence; however, the results were not significant any more after adjustment for multiple testing, and therefore, Newson et al. concluded that it is unlikely that CB serum fatty acid concentrations are an important risk factor for the later development of allergic diseases (15).

Several observational and interventional studies explored the association between atopic diseases and diet (7, 16–18) as well as maternal n-3 LC-PUFA status during pregnancy (19–24) or lactation (25–27).

In an earlier publication based on data from the LISAplus birth cohort, the association between maternal dietary intake during the last 4 wk of pregnancy and allergic diseases in the offspring up to the age of 2 yr was investigated (16). In this analysis, a higher intake of n-6 PUFA rich foods such as margarine and vegetable oils and a lower intake of n-3 PUFAs rich foods such as fish were associated with eczema in the offspring. In our analysis, we used exact measurements of the n-3 and n-6 LC-PUFA concentrations in CB serum instead of food intake as proxy but could not replicate this finding. However, in this study, we focused on LC-PUFAs, whereas margarine is rich in linoleic acid, which may mediate the effect, but was not considered in the current analysis. Additionally, our study population was limited to the Munich study center only and the sample size was reduced due to limited blood sample availability.

In fact, the most consistent evidence was found in studies focusing on dietary intake, especially on dietary fish intake as a source of n-3 PUFA (7, 16–18). Therefore, it has been hypothesized that a sufficient n-3 LC-PUFA supply may prevent from atopic diseases, especially during the pre- and early post-natal period when the immature immune system is developing (5, 28).

Some intervention studies have been conducted to investigate the association between n-3 LC-PUFA status and atopic diseases during pregnancy (19–24) or lactation (25–27). The studies in which cytokines were measured, reported a more favorable immune response (19–21, 25, 27).
results, whereas the exact measurement in blood is supposed to be more accurate.

In our study, we could not find a protective effect of n-3 LC-PUFA concentration in CB serum on any of the allergic diseases, as seen for the ALSPAC study (15). CB serum fatty acid composition represents the fatty acid supply of the fetus at birth. The models were adjusted for the fatty acid composition in blood at each follow-up to rule out confounding by lifestyle or dietary factors, which may be reflected in fatty acid concentrations in blood. The longitudinal study design increased this study’s statistical power, as the maximal number of observations available was included in the models, and allows modeling the effect of LC-PUFA in CB serum as well as at the follow-ups at several time points up to 10 yr of age. Due to the constraints of the longitudinal model, the variables for asthma, eczema, and hay fever/allergic rhinitis which were asked yearly had to be combined into the periods between the blood measurements to obtain the same time points. In a sensitivity analysis, general linear models were conducted for each follow-up. The results were similar for all follow-ups, and we could not identify a time-varying effect of CB serum fatty acids. Another limitation of this study is the potential bias associated with non-random loss to follow-up. A comparison of all investigated variables between participants who were included in this analysis and non-participants showed a significantly higher percentage of parents with high education level in the participants group, but no significant differences in all other investigated variables. However, a sensitivity analysis restricted to children with complete data for all times of follow-up showed similar results, but, only in this analysis, there was a borderline significant inverse association between n-6 LC-PUFA in CB serum and eczema. A further limitation is the relatively low habitual fish and seafood intake in Germany, compared with other European countries (30), leading to a limited range of n-3 LC-PUFA intakes, whereas some of the intervention studies found effects on immune response with high dosages of fish oil supplementation.

As observational and interventional studies on dietary intake of fatty acids and allergic diseases are inconclusive (18), we thought that prospectively collected and longitudinally analysed data on fatty acid composition in CB serum could elucidate the protective association. However, this study with data on repeated measurements of fatty acids during a period of 10 yr failed to show strong and consistent associations.

Clearly, further interventional studies with adequate sample size, long-term follow-up, and repeated measurements are required to confirm the role of n-3 and n-6 PUFAs in the development of atopic diseases.

Acknowledgments
This work was supported by grants 01 EG 9732, 01 EG 9705/2, and 01 EE 9401-4 from the Federal Ministry for Education, Science, Research, and Technology; FKZ 20462296 from the Federal Ministry of Environment; Ludwig-Maximilians-Universities’ innovative research priority Project MC-Health; the Commission of the European Communities, within the 7th Framework Programme, research grant no. FP7/2007-13 (EarlyNutrition Project), and the European Research Council, grant agreement n° 3226059. This abstract does not necessarily reflect the views of the Commission and in no way anticipates the future policy in this area. We thank all the families who participated in the LISAplus Study. Furthermore, we thank all members of the LISAplus Study group for their excellent work. We also acknowledge Larissa Piniek-Tzimourtas (University of Munich Medical Center, Dr von Hauner Children’s Hospital, Division of Metabolic and Nutritional Medicine, Munich, Germany) for her excellent contribution to the measurements of fatty acid composition. The LISAplus Study group consists of the following: Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Epidemiology, Munich (J Heinrich, HE Wichmann, S Sausenthaler, CM Chen, and M Schnappinger); Department of Pediatrics, Municipal Hospital ‘St. Georg,’ Leipzig (M Borie and U Diez); Marien-Hospital Wesel, Department of Pediatrics, Wesel (A von Berg, C Beckmann, and I Groß); Pediatric Practice, Bad Honnef (B Schaff); Helmholtz Centre for Environmental Research–UFZ, Department of Environmental Immunology/Core Facility Studies, Leipzig (I Lehmann, M Bauer, C Gräbsch, S Röder, and M Schilde); University of Leipzig, Institute of Hygiene and Environmental Medicine, Leipzig (O Herbarth, C Dick, and J Magnus); IUF–Institut für Umweltmedizinische Forschung, Düsseldorf (U Krämer, E Link, and C Cramer); Technical University Munich, Department of Pediatrics, Munich (CP Bauer and U Hoffmann); and ZAUM–Center for Allergy and Environment, Technical University, Munich (H Behrendt, J Grosch, and F Martin).

Conflict of interest
The authors declare no conflict of interests.

References
1. Calder PC, Miles EA. Fatty acids and atopic disease. Pediatr Allergy Immunol 2008; 11 (Suppl. 13): 29–36.
2. Devereux G. The increase in the prevalence of asthma and allergy: food for thought. Nat Rev Immunol 2006; 6: 869–74.
3. Calder PC. Polyunsaturated fatty acids and inflammation. Biochem Soc Trans 2005; 33: 423–7.
4. Prescott SL. Allergic disease: understanding how in utero events set the scene. Proc Nutr Soc 2010; 69: 366–72.
5. Calder PC, Kremmyda LS, Vlachava M, Noakes PS, Miles EA. Is there a role for fatty acids in early life programming of the immune system? Proc Nutr Soc 2010; 69: 373–80.
6. Larqué E, Gil-Sánchez A, Prieto-Sánchez MT, Koletzko B. Omega 3 fatty acids, gestation and pregnancy outcomes. Br J Nutr 2012; 107(Suppl. 2): S77–84.
7. Kremmyda LS, Vlachava M, Noakes PS, Diaper ND, Miles EA, Calder PC. Atopy risk in infants and children in relation to early exposure to fish, oily fish, or long-chain omega-3 fatty acids: a systematic review. Clin Rev Allergy Immunol 2011; 41: 36–66.
Cord blood LC-PUFA and allergies

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Participant flow.

Table S1. Comparison of all investigated variables between study participants and non-participants.

Table S2. Results of a GEE in which n-3, n-6 LC-PUFA concentrations, and n-6/n-3 ratio in cord blood (CB) serum are regressed on allergic diseases restricted to children with complete information on all time points.

Table S3. Results of general linear models in which n-3, n-6 LC-PUFA concentrations, and n-6/n-3 ratio in cord blood (CB) serum are regressed on allergic diseases stratified for each follow-up.